JNJ-61178104

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameJNJ-61178104

Drug Alias NameJNJ-61178104

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionTumor necrosis factor α inhibitorsInterleukin 17A inhibitors

TargetsTumor necrosis factor αInterleukin 17A

Therapy Area/IndicationsAutoimmune Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesJohnson & Johnson Innovative Medicine

China Registration ClassN/A

Develop Information

Active CompaniesJohnson & Johnson Innovative Medicine

Inactive CompaniesJanssen Research & Development Llc

Active IndicationsAutoimmune Diseases

Inactive IndicationsN/A

Other Information

ATC CodeN/A